PubMed haku 2.1. 2020.
https://www.ncbi.nlm.nih.gov/pubmed/?term=UDP-galactose
Best matches for UDP-galactose:
Cryptococcus neoformans UGT1 encodes a UDP-Galactose/UDP-GalNAc transporter.
Li LX et al. Glycobiology.
(2017)
One-Pot Synthesis of Hyperoside by a Three-Enzyme Cascade Using a UDP-Galactose Regeneration System.
Pei J et al. J Agric Food Chem.
(2017)
UDP-Glucose
4-Epimerase and β-1,4-Galactosyltransferase from the Oyster
Magallana gigas as Valuable Biocatalysts for the
Production of Galactosylated Products.
Song HB et al. Int J Mol Sci.
(2018)
Hakulöytöjä muuten seuraavat_
Search results "UDP-galactose"
Items: 1 to 20 of 2671
of 134
Next >Last >>- Poimin muutaman, jotka merkitsevät ihmisen (Homo sapiens) kannalta olennaista:
Löytöjä:
https://www.ncbi.nlm.nih.gov/pubmed/?term=UDP-galactose++homo+sapiens
Best matches for UDP-galactose homo sapiens:
Hereditary galactosemia.
Demirbas D et al. Metabolism.
(2018)
Cryptococcus neoformans UGT1 encodes a UDP-Galactose/UDP-GalNAc transporter.
Li LX et al. Glycobiology.
(2017)
Inherited thrombocytopenia associated with mutation of UDP-galactose-4-epimerase (GALE).
Seo A et al. Hum Mol Genet.
(2019).
Search results
Items: 1 to 20 of 902
of 46
Next >- Artikkeleita kahden viime vuoden ajalta:
Lv X, Chen Y, Luo Y, Li L, Wang H.
Medicine (Baltimore). 2019 Aug;98(31):e16361. doi: 10.1097/MD.0000000000016361.
OUTCOMES:The patient was the rare p phenotype in P1P blood
system and the patient's habitual abortion was caused by anti-PP1P
antibody which was generated naturally in persons with p phenotype.
There was a mutation (903C>G, CCC>CCG) in the 3rd exon of A4GALT
gene, which is likely a significant contributor to p phenotype.LESSONS: This
is the first case of habitual abortion caused by p phenotype due to
independent 903C>G homozygous mutation with no similar record
reported before, which indicates that it is a new class of mutation that
leads to p phenotype.
Free PMC Article ( Asetan linkin Veri ja hyytyminen- blogiini 2.1. 2020 veriryhmätietojen joukkoon)
Free PMC Article ( Asetan linkin Veri ja hyytyminen- blogiini 2.1. 2020 veriryhmätietojen joukkoon)
2.
Ha C, Choi S, Yu H, Chun S, Kim KH, Lee JH, Han IW, Cho D.
Ann Lab Med. 2019 Nov;39(6):602-605. doi: 10.3343/alm.2019.39.6.602. No abstract available.Free PMC Article
3.
Yang YD, Xu LL, Li DZ.
Eur J Obstet Gynecol Reprod Biol. 2019 May;236:257-258. doi: 10.1016/j.ejogrb.2019.03.013. Epub 2019 Mar 19. No abstract available.
4.
Prakash O, Führing J, Post J, Shepherd SM, Eadsforth TC, Gray D, Fedorov R, Routier FH.
Molecules. 2019 Mar 12;24(5). pii: E996. doi: 10.3390/molecules24050996.
Leishmania parasites additionally express a UDP-sugar pyrophosphorylase (USP) responsible for monosaccharides salvage that is able to generate both UDP-Gal and UDP-Glc.
The inactivation of the two parasite pyrophosphorylases UGP and USP,
results in parasite death.
The present study reports on the
identification of structurally diverse scaffolds for the development of
USP inhibitors by fragment library screening. Based on this screening,
we selected a small set of commercially available compounds, and
identified molecules that inhibit both Leishmania major USP and
UGP, with a half-maximal inhibitory concentration in the 100 µM range.
The inhibitors were predicted to bind at allosteric regulation sites,
which were validated by mutagenesis studies. This study sets the stage
for the development of potent USP inhibitors.Free PMC Article
Similar articles (Asetan 2.1. 2020 tämän linkin blogiin INFEKTIOISTA)
5.
Demirbas D, Huang X, Daesety V, Feenstra S, Haskovic M, Qi W, Gubbels CS, Hecht L, Levy HL, Waisbren SE, Berry GT.
Mol Genet Metab. 2019 Apr;126(4):368-376. doi: 10.1016/j.ymgme.2019.01.016. Epub 2019 Jan 22.
GALT deficiency is a rare genetic disorder of carbohydrate metabolism. Due to the decreased activity or absence of the enzyme galactose-1-phosphate uridylyltransferase (GALT), cells from affected individuals are unable to metabolize galactose
normally. Lactose consumption in the newborn period could potentially
lead to a lethal disease process with multi-organ involvement. In
contrast to the newborn-stage disease, however, a galactose-restricted
diet does not prevent long-term complications such as central nervous
system (CNS) dysfunction with speech defects, learning disability and
neurological disease in addition to hypergonadotropic hypogonadism or
primary ovarian insufficiency (POI) in females. As the literature
suggests an association between GALT enzyme activity and the long-term
complications, it is of importance to have a highly sensitive assay to
quantify the GALT enzyme activity. To that end, we had developed a
sensitive and accurate LC-MS/MS method to measure GALT enzyme activity.
Its ability to predict outcome is the subject of this report.RESULTS:
The LC-MS/MS method measured GALT activity as low as 0.2%, whereas other methods showed no detectable activity. Largely due to GALT activities that were over 1%, the LC-MS/MS measurements were not significantly different than values obtained in other laboratories using other methodologies. Severe long-term complications were less frequently noted in subjects with >1% activity. Patients with a p.Q188R/p.Q188R genotype have no residual enzyme activity in erythrocytes.CONCLUSION:
Our LC-MS/MS assay may be necessary to accurately quantify residual GALT activities below 5%. The data suggest that patients with >1% residual activity are less likely to develop diet-independent long-term complications. However, much larger sample sizes are needed to properly assess the clinical phenotype in patients with residual enzyme activities between 0.1 and 5%.
The LC-MS/MS method measured GALT activity as low as 0.2%, whereas other methods showed no detectable activity. Largely due to GALT activities that were over 1%, the LC-MS/MS measurements were not significantly different than values obtained in other laboratories using other methodologies. Severe long-term complications were less frequently noted in subjects with >1% activity. Patients with a p.Q188R/p.Q188R genotype have no residual enzyme activity in erythrocytes.CONCLUSION:
Our LC-MS/MS assay may be necessary to accurately quantify residual GALT activities below 5%. The data suggest that patients with >1% residual activity are less likely to develop diet-independent long-term complications. However, much larger sample sizes are needed to properly assess the clinical phenotype in patients with residual enzyme activities between 0.1 and 5%.
6.
Sosicka P, Bazan B, Maszczak-Seneczko D, Shauchuk Y, Olczak T, Olczak M.
Int J Mol Sci. 2019 Jan 11;20(2). pii: E276. doi: 10.3390/ijms20020276.
7.
Lane
WJ, Aguad M, Smeland-Wagman R, Vege S, Mah HH, Joseph A, Blout CL,
Nguyen TT, Lebo MS, Sidhu M, Lomas-Francis C, Kaufman RM, Green RC,
Westhoff CM; MedSeq Project.
Transfusion. 2019 Mar;59(3):908-915. doi: 10.1111/trf.15089. Epub 2018 Dec 28.
(Viite veriryhmätekijöiden joukkoon Veri ja hyytyminen blogiini 2.1. 2020)
(Viite veriryhmätekijöiden joukkoon Veri ja hyytyminen blogiini 2.1. 2020)
8.
Chatterjee SB, Hou J, Bandaru VVR, Pezhouh MK, Syed Rifat Mannan AA, Sharma R.
Biochem Biophys Res Commun. 2019 Jan 8;508(2):380-386. doi: 10.1016/j.bbrc.2018.11.149. Epub 2018 Nov 28.
- PMID:
- 30502090
9.
Zhang Y, Zheng Y, Li J, Nie L, Hu Y, Wang F, Liu H, Fernandes SM, Zhong Q, Li X, Schnaar RL, Jia Y.
Life Sci. 2019 Jan 1;216:189-199. doi: 10.1016/j.lfs.2018.11.049. Epub 2018 Nov 22.
- PMID:
- 30471282
10.
Bilyard MK, Bailey HJ, Raich L, Gafitescu MA, Machida T, Iglésias-Fernández J, Lee SS, Spicer CD, Rovira C, Yue WW, Davis BG.
Nature. 2018 Nov;563(7730):235-240. doi: 10.1038/s41586-018-0644-7. Epub 2018 Oct 24.
- PMID:
- 30356213
11.
Michelet R, Van Bocxlaer J, Allegaert K, Vermeulen A.
J Pharmacokinet Pharmacodyn. 2018 Dec;45(6):765-785. doi: 10.1007/s10928-018-9607-8. Epub 2018 Oct 8.
- PMID:
- 30298439
12.
Seo A, Gulsuner S, Pierce S, Ben-Harosh M, Shalev H, Walsh T, Krasnov T, Dgany O, Doulatov S, Tamary H, Shimamura A, King MC.
Hum Mol Genet. 2019 Jan 1;28(1):133-142. doi: 10.1093/hmg/ddy334.
13.
Kurz J, Brunkhorst R, Foerch C, Blum L, Henke M, Gabriel L, Ulshöfer T, Ferreirós N, Parnham MJ, Geisslinger G, Schiffmann S.
Clin Sci (Lond). 2018 Aug 17;132(17):1963-1976. doi: 10.1042/CS20180506. Print 2018 Sep 14.
In white blood cells, C16-LacCer and
C24-Cer were down-regulated in MS patients in comparison with healthy
controls.
In plasma, C16-Cer, C24:1-Cer, C16-GluCer, and C24:1-GluCer
were up-regulated and
C16-LacCer was down-regulated in MS patients in
comparison with healthy controls.
Blood samples from MS patients were
characterized by an increased B-cell number. However, there was no
correlation between B-cell number and Cer levels. mRNA expression of Cer
metabolizing enzymes and G-CSF signaling enzymes was significantly
increased in MS patients.
Interestingly, G-CSF receptor (G-CSFR) and
CXCR2 mRNA expression correlated with CerS2 and UDP-glucose
Cer glucosyltransferase (UGCG) mRNA expression.
In conclusion, our
results indicate that Cer metabolism is linked to G-CSF signaling in MS.
14.
Yates
TM, Suri M, Desurkar A, Lesca G, Wallgren-Pettersson C, Hammer TB,
Raghavan A, Poulat AL, Møller RS, Thuresson AC, Balasubramanian M.
Eur J Paediatr Neurol. 2018 Nov;22(6):1095-1102. doi: 10.1016/j.ejpn.2018.08.002. Epub 2018 Aug 27.
- PMID:
- 30194038
15.
Hattori T, Watanabe-Takahashi M, Nishikawa K, Naito M.
Biol Pharm Bull. 2018;41(9):1475-1479. doi: 10.1248/bpb.b18-00277.
- PMID:
- 30175782
16.
Klein
MC, Zimmermann K, Schorr S, Landini M, Klemens PAW, Altensell J, Jung
M, Krause E, Nguyen D, Helms V, Rettig J, Fecher-Trost C, Cavalié A,
Hoth M, Bogeski I, Neuhaus HE, Zimmermann R, Lang S, Haferkamp I.
Nat Commun. 2018 Aug 28;9(1):3489. doi: 10.1038/s41467-018-06003-9.
17.
van Weeghel M, Welling L, Treacy EP, Wanders RJA, Ferdinandusse S, Bosch AM.
Orphanet J Rare Dis. 2018 Aug 24;13(1):146. doi: 10.1186/s13023-018-0888-1.
18.
Westenfield K, Sarafoglou K, Speltz LC, Pierpont EI, Steyermark J, Nascene D, Bower M, Pierpont ME.
BMC Med Genet. 2018 Jun 15;19(1):100. doi: 10.1186/s12881-018-0617-6.
- PMID:
- 29907092
19.
Pierdominici-Sottile G, Cossio-Pérez R, Da Fonseca I, Kizjakina K, Tanner JJ, Sobrado P.
Biochemistry. 2018 Jul 3;57(26):3713-3721. doi: 10.1021/acs.biochem.8b00323. Epub 2018 May 18.
- PMID:
- 29757624
20.
Kaczmarek
R, Szymczak-Kulus K, Bereźnicka A, Mikołajczyk K, Duk M, Majorczyk E,
Krop-Watorek A, Klausa E, Skowrońska J, Michalewska B, Brojer E,
Czerwinski M.
PLoS One. 2018 Apr 30;13(4):e0196627. doi: 10.1371/journal.pone.0196627. eCollection 2018.
Contrary to the mainstream blood group systems, P1PK continues to puzzle
and generate controversies over its molecular background. The P1PK
system comprises three glycosphingolipid antigens: Pk, P1 and NOR, all
synthesised by a glycosyltransferase called Gb3/CD77 synthase. The Pk
antigen is present in most individuals, whereas P1 frequency is lesser
and varies regionally, thus underlying two common phenotypes: P1, if the
P1 antigen is present, and P2, when P1 is absent. Null and NOR
phenotypes are extremely rare.
To date, several single nucleotide
polymorphisms (SNPs) have been proposed to predict the P1/P2 status, but
it has not been clear how important they are in general and in relation
to each other, nor has it been clear how synthesis of NOR affects the
P1 phenotype. Here, we quantitatively analysed the phenotypes and A4GALT
transcription in relation to the previously proposed SNPs in a sample
of 109 individuals, and addressed potential P1 antigen level
confounders, most notably the red cell membrane cholesterol content.
While all the SNPs were associated with the P1/P2 blood type and
rs5751348 was the most reliable, we found large differences in P1 level
within groups defined by their genotype and substantial intercohort
overlaps, which shows that the P1PK blood group system still eludes full
understanding.Free PMC Article
Inga kommentarer:
Skicka en kommentar